Abstract: [Problem to be Solved] The present invention provides a method for producing a chimeric animal using a primed pluripotent stem cell, a tissue stem cell, a progenitor cell, a somatic cell, or a germ cell. [Solution] The method for producing a chimeric animal according to the present invention comprises introducing a mammal-derived cell into the embryo of a mammal, the cell being primed pluripotent stem cell, tissue stem cell, progenitor cell, somatic cell, or germ cell.

Abstract: The present invention provides methods for diagnosing mental disorders (e.g., psychotic disorders such as schizophrenia and mood disorders such as major depression disorder and bipolar disorder). The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders.

Abstract: Pharmaceutical formulations of glutenase enzymes are provided. The enzymes find particular use in the treatment of a Celiac or dermatitis herpetiformis patient.

Abstract: An insulated lattice is prepared with a plurality of lattice oriented atoms to create a substantially planar surface having a lattice arrangement. Any unsatisfied chemical bonds are terminated along the substantially planar surface by placing atoms at the site of the unsatisfied chemical bonds to terminate the unsatisfied chemical bonds and insulate the surface to form a platform. In one aspect of the invention, the insulator atoms are removed at predetermined locations. Atoms to form the atomic chain are placed at predetermined locations on the insulated lattice platform to form a first atomic chain which behaves as one of a conductor, a semiconductor and an insulator. A second atomic chain is also placed at predetermined locations on the insulated lattice platform so that the second chain behaves as another of a conductor, a semiconductor and an insulator.

Abstract: A method to determine the site on a receptor or its cognate signaling pathway at which an antagonist acts is disclosed. The method comprises first, (a) determining the effect of an antagonist on a first cell that has been modified to display a mutant form of said receptor. The mutant form constituitively activates the cognate signaling pathway of said receptor. Second, (b) the effect of the antagonist is determined on a second host cell that has been modified to display a tethered form of the receptor. The tethered form is composed of an agonist for said receptor covalently bound thereto whereby said agonist activates the cognate signaling pathway of said receptor. The effect on the cells is determined by measuring the level of an intracellular event that is responsive to the cognate signaling pathway. An antagonist that inhibits the intracellular event in (b) acts at the site of binding for an agonist to the receptor.

Abstract: The present invention provides compositions comprising a peptide having between about 7 and about 20 amino acid residues, the peptide being capable of binding a CD8 molecule on a cytolytic T lymphocyte (CTL) precursor and inhibiting differentiation of the CTL precursor to a mature CTL. The peptides have amino acid sequences substantially homologous to a sequence in an .alpha.3 domain of a human Class I MHC molecule. The sequence from the .alpha.3 domain is preferably between residue 220 and residue 235. The peptides typically comprise the sequences DQTQDTE (SEQ. ID No. 1) or EDQTQDTELVETRP (SEQ. ID No. 2).